Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02482376
• Other study ID #: Pro00063848
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 21, 2015
• Est. completion date: March 2032

Study information

• Verified date: October 2023
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This protocol seeks to build on the favorable results of the investigators' phase I trial (Pro00015617) by extending the findings to a larger cohort of subjects.In this study, the investigators hypothesize that 21Gy (Gray) as a single fraction can be delivered preoperatively to a larger group of subjects (n100).

The primary objective is to determine physician reported rates of good/excellent cosmesis at baseline and 6 months, 1, 2, and 3 years post-treatment as measured by the NRG cosmesis scale

Description:

The study team hypothesizes that a single fraction of 21Gy can be delivered preoperatively to the intact breast tumor with acceptable cosmetic outcomes. Furthermore, the investigators anticipate that pre- and post-radiation breast tumor samples will provide an avenue for understanding breast cancer radiation response

Rationale for single-fraction preoperative technique

This trial is proposed to build on the favorable results of the investigators' phase I trial by extending the findings to a larger cohort of subjects. The preoperative approach has several advantages:

1. a small intact breast tumor results in significantly less uninvolved breast tissue receiving high radiation doses which likely decreases toxicity;

2. more accurate targeting of the high-risk areas of subclinical disease surrounding the tumor is possible,

3. smaller treatment volumes are amenable to dose escalation which can further accelerate treatment and improve accessibility for subjects,

4. this technical approach is widely utilized in other tumor sites and can be delivered at most radiation facilities

5. the pre-operative approach provides a novel opportunity to study breast cancer radiation response.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 68
• Est. completion date: March 2032
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast

a. Biopsy tissue (either slides or block) from outside institutions will be reviewed to confirm diagnosis.

2. Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric or multifocal disease, no pregnant women, and no comorbid conditions precluding surgery)

3. Clinical T1N0M0 invasive carcinoma or Ductal carcinoma in situ (DCIS) < or equal to 2cm

4. 60 years of age or older or 50-59 with a low Oncotype score (0-17) Oncotype is not required for women diagnosed with DCIS.

5. Estrogen receptor positive (ER+), Human epidermal growth factor 2 negative (HER2-) HER-2 status is not required for women diagnosed with DCIS.

6. Women of child-bearing potential must consent to use adequate contraception during the course of the study. Female subjects must agree to use a medically acceptable contraceptives including: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use.

7. White blood cells (WBC) > 3000, Hemoglobin ( Hgb) > 9, platelets >100000 within 30 days of consent

8. Eligible for contrasted magnetic resonance imaging (MRI) on initial evaluation with glomerular filtration rate (GFR) = 60 ml/min. A diagnostic MRI ordered within one month will be considered an acceptable alternative and will not be repeated.

9. Outside breast imaging will be reviewed at Duke to confirm findings are consistent with trial eligibility.

Exclusion Criteria:

1. Neoadjuvant chemotherapy

2. Breast implant in the breast to be treated with SBRT

3. Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)

4. Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach at length

5. HER2 positive

6. Positive serum pregnancy test

7. Insufficient breast imaging to judge clinical stage

8. Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement.

9. Subjects in whom treatment planning constraints cannot be met

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Radiation:
• Stereotactic body radiotherapy ( SBRT)
Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer

Locations

Country	Name	City	State
United States	Duke Cancer Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Gateway for Cancer Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physician reported rates of good/excellent cosmesis.	Physician will independently complete the physician NRG Oncology cosmesis scale at the designated time points	Through study completion estimated to be 3 years
Secondary	Ki-67 will be assessed as a measure of tumor response	Ki-67 will be assessed in the pre and post radiotherapy tissue samples	Through study completion estimated to be 3 years
Secondary	Patient reported rates of good/excellent cosmesis	Patients will independently complete the patient NRG Oncology cosmesis scale at designated timepoints	Through study completion estimated to be 3 years
Secondary	The impact of radiation on gene expression	Gene expression will be assessed using the Affymetrix Human Transcriptome Array (HTA) arrays designed for formalin fixed paraffin embedded (FFPE) samples on pre and post radiation therapy tissue samples.	Through study completion estimated to be 3 years
Secondary	Local control in the treated breast relative to historic controls	Annual clinical examination combined with breast imaging	Through study completion estimated to be 5-10 years
Secondary	Assess the impact of RT on circulating cell free DNA	Oxidative stress biomarkers will be measured in serum and urine collected at the same timepoints	Through study completion estimated to be 3 years